Nanotechnology could improve our understanding of the pathophysiology of atherosclerosis
and contribute to the development of novel diagnostic and therapeutic strategies to further …

Animal studies are a foundation for defining mechanisms of atherosclerosis and potential
targets of drugs to prevent lesion development or reverse the disease. In the current …

Associations between per-and polyfluoroalkyl substances (PFASs) and increased blood
lipids have been repeatedly observed in humans, but a causal relation has been debated …

Background and aims The recently developed histological scoring system for non-alcoholic
fatty liver disease (NAFLD) by the NASH Clinical Research Network (NASH-CRN) has been …

Atherosclerotic cardiovascular disease is a major cause of death among humans. Animal
models have shown that cholesterol and inflammation are causatively involved in the …

Atherosclerotic cardiovascular disease (CVD), the major cause of premature human
mortality, is a chronic and progressive metabolic and inflammatory disease in large-and …

Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol
(HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that …

Atherosclerosis is one of the primary causes of cardiovascular disease and mortality. This
chronic immunometabolic disease evolves during decades in humans and encompasses …

Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising
therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 …

Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that
work synergistically to promote lesion development. The ability to develop preventive and …